Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target

Author(s): Luca Miele, Giuseppe Marrone, Cristiano Lauritano, Consuelo Cefalo, Antonio Gasbarrini, Chris Day and Antonio Grieco

Volume 19, Issue 29, 2013

Page: [5314 - 5324] Pages: 11

DOI: 10.2174/1381612811319290011

Price: $65

Abstract

There is increasing evidence for a correlation between intestinal microbiota, bacterial translocation and hepatic steatosis. Intestinal microbiota affects nutrient absorption and energy homeostasis. Altered intestinal permeability may favor the passage of bacteriaderived compounds into systemic circulation, causing a systemic inflammatory state, characteristic of the metabolic syndrome. The interaction between intestinal permeability and luminal bacteria is involved in the pathogenesis and evolution of non-alcoholic liver disease. Microbiota pharmacological modulation could be a promising tool for a new therapeutical approach to non-alcoholic fatty liver disease.

Keywords: Gut-liver axis, intestinal permeability, insulin resistance, human microbiota, NAFLD, portal hypertension.

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy